The effect of acetylsalicylic acid resistance on prognosis of patients who have developed acute coronary of patients who have developed acute coronary syndrome during acetylsalicylic acid therapy

Canadian Journal of Cardiology

Volumn 23, Issue 3, 2007, Pages 201-206

  Hobikoglu, Gultekin F ^a,c   Norgaz, Tugrul ^a   Aksu, Huseyin ^a   Ozer, Orhan ^a   Erturk, Mehmet ^a   Destegul, Evren ^a   Akyuz, Umit ^b   Dai, Sennur Unal ^a   Narin, Ahmet ^a  

^a DR SIYAMI ERSEK THORACIC AND CARDIOVASCULAR SURGERY TRAINING AND RESEARCH HOSPITAL   (Turkey)

^b HAYDARPASA NUMUNE HOSPITAL   (Turkey)

^c NONE   (Turkey)

Author keywords

Acetylsalicylic acid resistance; Acute coronary syndrome; Prognosis

Indexed keywords

ACETYLSALICYLIC ACID; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CLOPIDOGREL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; TICLOPIDINE; TROPONIN T; ANTITHROMBOCYTIC AGENT; BIOLOGICAL MARKER;

ACUTE CORONARY SYNDROME; ADULT; AGE DISTRIBUTION; AGED; ANALYZER; ANGIOCARDIOGRAPHY; ANTICOAGULANT THERAPY; ARTICLE; CEREBROVASCULAR ACCIDENT; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CORRELATION ANALYSIS; DEATH; DISEASE SEVERITY; FEMALE; FOLLOW UP; HEART INFARCTION; HEART MUSCLE INJURY; HEART MUSCLE REVASCULARIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTCOMES RESEARCH; PREDICTION; PROGNOSIS; PROSPECTIVE STUDY; SCORING SYSTEM; THROMBOCYTE COUNT; THROMBOCYTE FUNCTION; ANALYSIS OF VARIANCE; BIOASSAY; BLOOD; CONTROLLED CLINICAL TRIAL; CORONARY ARTERY ATHEROSCLEROSIS; DRUG EFFECT; DRUG RESISTANCE; HOSPITALIZATION; METHODOLOGY; MIDDLE AGED; PREDICTION AND FORECASTING; RADIOGRAPHY; SYNDROME; TIME; TREATMENT OUTCOME;

AGED; ANALYSIS OF VARIANCE; ASPIRIN; BIOLOGICAL MARKERS; CONTROLLED CLINICAL TRIALS; CORONARY ANGIOGRAPHY; CORONARY ARTERIOSCLEROSIS; DRUG RESISTANCE; ENDPOINT DETERMINATION; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PLATELET AGGREGATION INHIBITORS; PLATELET COUNT; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROSPECTIVE STUDIES; RESEARCH DESIGN; SEVERITY OF ILLNESS INDEX; SYNDROME; TIME FACTORS; TREATMENT OUTCOME; TROPONIN T;

EID: 34247203122     PISSN: 0828282X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0828-282X(07)70744-4     Document Type: Article

References (36)

1. Mehta J, Mehta P, Feldman RL, Horalek C. Thromboxane release in coronary artery disease: Spontaneous versus pacing-induced angina. Am Heart J 1984;107:286-92.
2. Fitzgerald DJ, Roy L, Catella F, FitzGerald GA. Platelet activation in unstable coronary disease. N Engl J Med 1986;315:983-9.
3. Hirsh PD, Hillis D, Campbell WB, Firth BG, Willerson JT. Release of prostaglandins and thromboxane into the coronary circulation in patients with ischemic heart disease. N Engl J Med 1981;304:685-91.
4. Mizuno K, Satomura K, Miyamoto A, et al. Angioscopic evaluation of coronary artery thrombi in acute coronary syndromes. N Engl J Med 1992;326:287-91.
5. Davies MJ. Stability and instability: Two faces of coronary atherosclerosis. The Paul Dudley White Lecture 1995. Circulation 1996;94:2013-20.
6. Lewis HD Jr, Davis JW, Archibald DG, et al. Protective effects of aspirin against acute myocardial infarction and death in men with unstable angina. Results of a Veterans Administration Cooperative Study. N Engl J Med 1983;309:396-403.
7. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Lancet 1988;2:349-60.
8. Gum PA, Kottke-Marchant K, Poggio ED, et al. Profile and prevalence of aspirin resistance in patients with cardiovascular disease. Am J Cardiol 2001;88:230-5.
9. Helgason CM, Tortorice KL, Winkler SR, et al. Aspirin response and failure in cerebral infarction. Stroke 1993;24:345-50.
10. Pappas JM, Westengard JC, Bull BS. Population variability in the effect of aspirin on platelet function. Implications for clinical trials and therapy. Arch Pathol Lab Med 1994;118:801-4.
11. Grotemeyer KH. Effects of acetylsalicylic acid in stroke patients. Evidence of nonresponders in a subpopulation of treated patients. Thromb Res 1991;63:587-93.
12. Valles J, Santos MT, Aznar J, et al. Erythrocyte promotion of platelet reactivity decreases the effectiveness of aspirin as an antithrombotic therapeutic modality: The effect of low-dose aspirin is less than optimal in patients with vascular disease due to prothrombotic effects of erythrocytes on platelet reactivity. Circulation 1998;97:350-5.
13. Hobikoglu GF, Norgaz T, Aksu H, et al. [Evaluation of aspirin resistance in patients with coronary artery disease. J Arch Turk Soc Cardiol 2005;33:212-6.
14. Cattaneo M. Aspirin and clopidogrel: Efficacy, safety, and the issue of drug resistance. Arterioscler Thromb Vasc Biol 2004;24:1980-7.
15. Patrono C. Aspirin resistance: Definition, mechanisms and clinical read-outs. J Thromb Haemost 2003;1:1710-3.
16. Hankey GJ, Eikelboom JW. Aspirin resistance. Lancet 2006;367:606-17.
17. Helgason CM, Bolin KM, Hoff JA, et al. Development of aspirin resistance in persons with previous ischemic stroke. Stroke 1994;25:2331-6.
18. Macchi L, Christiaens L, Brabant S, et al. Resistance in vitro to low-dose aspirin is associated with platelet PlA1 (GP IIIa) polymorphism but not with C807T(GP Ia/IIa) and C-5T Kozak (GP Ibalpha) polymorphisms. J Am Coll Cardiol 2003;42:1115-9.
19. Undas A, Sanak M, Musial J, Szczeklik A. Platelet glycoprotein IIIa polymorphism, aspirin and thrombin generation. Lancet 1999;353:982-3.
20. Cipollone F, Patrignani P, Greco A, et al. Differential suppression of thromboxane biosynthesis by indobufen and aspirin in patients with unstable angina. Circulation 1997;96:1109-6.
21. Weber AA, Zimmermann KC, Meyer-Kirchrath J, Schror K. Cyclooxygenase-2 in human platelets as a possible factor in aspirin resistance. Lancet 1999;353:900-3.
22. Macchi L, Christiaens L, Brabant S, et al. Resistance to aspirin in vitro is associated with increased platelet sensitivity to adenosine diphosphate. Thromb Res 2002;107:45-9.
23. Alexander JH, Harrington RA, Tuttle RH, et al. Prior aspirin use predicts worse outcomes in patients with non-ST-elevation acute coronary syndromes. PURSUIT Investigators. Platelet IIb/IIIa in Unstable angina: Receptor Suppression Using Integrilin Therapy. Am J Cardiol 1999;83:1147-51.
24. Hobikoglu GF, Norgaz T, Aksu H, et al. High frequency of aspirin resistance in patients with acute coronary syndrome. Tohoku J Exp Med 2005;207:59-64.
25. Kundu SK, Heilmann EJ, Sio R, Garcia C, Ostgaard RA. Characterization of an in vitro platelet function analyzer PFA-100. Clin Appl Thromh Hemost 1996;2:241-9.
26. Gensini GG. Coronary Arteriography. Mount Kisco: Futura Publishing Company, 1975:488.
27. Negri M, Sheiban I, Arigliano PL, et al. Interrelation between angiographic severity of coronary artery disease and plasma levels of insulin, C-peptide and plasminogen activator inhibitor-1. Am J Cardiol 1993;72:397-401.
28. Gum PA, Kottke-Marchant K, Welsh PA, White J, Topol EJ. A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease. J Am Coll Cardiol 2003;41:961-5. (Erratum in 2006;48:1918).
29. Eikelboom JW, Hirsh J, Weitz JI, Johnston M, Yi Q, Yusuf S. Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events. Circulation 2002;105:1650-5.
30. Stejskal D, Vaclavik J, Lacnak B, Proskova J. Aspirin resistance measured by cationic propyl gallate platelet aggregometry and recurrent cardiovascular events during 4 years of follow-up. Eur J Intern Med 2006;17:349-54.
31. Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction. Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) Study Investigators. N Engl J Med 1998;338:1488-97. (Erratum in 1998;339:415).
32. Mehta SR, Yusuf S, Peters RJ, et al; Clopidogrel in Unstable angina to prevent Recurrent Events trial (CURE) Investigators. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: The PCI-CURE study. Lancet 2001;358:527-33.
33. Barsky AA, Arora RR. Clopidogrel resistance: Myth or reality? J Cardiovasc Pharmacol Ther 2006;11:47-53.
34. Gurbel PA, Lau WC, Bliden KP, Tantry US. Clopidogrel resistance: Implications for coronary stenting. Curr Pharm Des 2006;12:1261-9.
35. Cassar K, Bachoo P, Ford I, Greaves M, Brittenden J. Variability in responsiveness to clopidogrel in patients with intermittent claudication. Eur J Vasc Endovasc Surg 2006;32:71-5.
36. Lev EI, Patel RT, Maresh KJ, et al. Aspirin and clopidogrel drug response in patients undergoing percutaneous coronary intervention: The role of dual drug resistance. J Am Coll Cardiol 2006;47:27-33.